ATS 2024 Final Program

Click on the session title to view the speakers

321

WEDNESDAY • MAY 22

811 The High Affinity Anti-IL-33 Antibody Itepekimab Potently Blocks IL-33 Induced Activation of the ST2/IL-1RAcP Signaling Complex and Inhibits Key Mediators of Airway Inflammation 812 Blocking IL-25 Inhibits Pulmonary Neutrophilic Inflammation During Rhinovirus Exacerbation of Allergic Airways Disease 813 Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Mouse Model of Asthma 814 Intranasal Allergen Exposure Drives Lymphoid Aggregate Formation, Local Class-switching and Ige + Plasma Cell Accumulation in the Lung 815 CFTR Prevents Type 2 Inflammation by Reducing IL-4 Signaling in Th2 Cells 816 Protective Role of Nrf2 in HDM-induced Neutrophilic Airway Inflammation 817 Gs Biased Positive Allosteric Modulation of Beta 2 Adrenergic Receptor Signaling Increases Antiviral Response in Cultured Human Bronchial Epithelial Cells 818 A Multiple Ascending-dose Study With Verekitug, A Novel Antibody to the Human Thymic Stromal Lymphopoietin Receptor, in Adults With Asthma 819 Proteomic and Transcriptomic Analysis of Residual Steroid-responsive Inflammation in Mepolizumab Treated Patients 820 Pulmonary Innate Lymphoid Type II Cells in Perinatal Vaping-induced Asthma in Offspring 821 Biased Signaling of Chemokine Receptor CCR1 in Asthma 822 The Asthma Impairment and Risk Questionnaire (AIRQ ® ) Predicts Exacerbation Risk in Patients With Mild-to-Moderate and Severe Disease 823 TSLP Responses to Rhinovirus Infection by Bronchial Epithelium From Children With T2 High and T2 Low Asthma, With and Without History of Severe Exacerbation 824 Efficacy and Safety of Rilzabrutinib - A Novel Oral Treatment in Asthma: Results From a Double Blind Placebo Controlled Phase 2 Study

BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

D21 TERMINATOR: CONTROL OF AIRWAY INFLAMMATION AND IMMUNE RESPONSE IN ASTHMA 8:15 a.m. - 10:15 a.m. San Diego Convention Center Room 31A-C (Upper Level) Poster Viewing 8:15-9:00 Discussion 9:00-10:15 801 Rhinovirus Replication and Innate Immune Responses in Bronchial Epithelium From Children With Severe Asthma Exacerbation History 802 T2 Inflammation Predicts Severity More Strongly in T1/CCL5 High Asthma Than in T1/CCL5 Low Asthma 803 Rev-erb a Agonist (SR9009) Attenuates House Dust Mite (HDM)-induced Lung Inflammation in a Preclinical Mouse Model of Allergic Asthma 804 IRL201104, A Novel Immunomodulatory Peptide, Shows Efficacy on Inflammatory Endpoints and Airway Hyperresponsiveness in a House Dust Mite Driven Model of Allergic Inflammation With or Without Poly I:C Exacerbation 805 High Airway Interleukin (IL)-6 Is Associated With Increased Blood IL-6 in Asthma Following Segmental Bronchoprovocation With Allergen 806 Innate Immune Mechanisms Associated With Exacerbations on Mepolizumab 807 A Peptide Fragment of the Actin-binding Protein Gelsolin Attenuates IgE-mediated Mast Cell Degranulation In Vitro and Murine Mast Cell Calcium Oscillations Ex Vivo 808 miR-15a-5p Has Vitamin A-dependent Effect on Lung Volume in Children With Asthma 809 Mast Cell Immune Responses to Primary Infection With Human Rhinovirus A16 Are Differentially Regulated by the Airway Epithelium 810 Differential Epithelial Responses to Allergen in Type 1 and Type 2 Inflammatory Environments

ATS 2024 • San Diego, CA